Reuters logo
FDA declines to approve PTC's Duchenne Muscular Dystrophy drug
2017年10月25日 / 下午4点36分 / 1 个月前

FDA declines to approve PTC's Duchenne Muscular Dystrophy drug

Oct 25 (Reuters) - The U.S. Food and Drug Administration has declined to approve PTC Therapeutics Inc’s experimental drug to treat Duchenne muscular dystrophy, saying an additional clinical trial would be needed to prove the drug works.

The company said it strongly disagreed with the agency’s conclusions and plans to file a formal dispute resolution next week. (Reporting by Toni Clarke in Washington)

我们的标准:汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below